Interferon beta tied to spike in thrombotic microangiopathy

Interferon beta tied to spike in thrombotic microangiopathy

(HealthDay)—There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant interferon beta, according to a letter to the editor published in the March 27 issue of the New England Journal of Medicine.

David Hunt, Ph.D., from Edinburgh University in the United Kingdom, and colleagues reviewed case histories and pharmacy records to describe an unexpectedly high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in four patients with who were receiving therapy with recombinant interferon beta in South Scotland. All patients presented after years of well-tolerated treatment with interferon beta.

The researchers found no genetic or other causal factor for thrombotic microangiopathy, but did note a significant association with a common manufacturing source of interferon beta (Rebif, Merck). Geographical and temporal distribution of the hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura reports shows that very few cases were reported globally in the first nine years of safety monitoring, but that there has been a recent increase in reports from countries that share the same formulation as that used in the United Kingdom.

"We did not detect such patterns or trends in the safety data from a similar recombinant product, suggesting that further investigation of the association with changes in manufacturing may be worthwhile," the authors write.

More information: Full Text

add to favorites email to friend print save as pdf

Related Stories

New link found between MS treatment and vitamin D

Jul 30, 2012

(Medical Xpress) -- A new study by researchers at the Menzies Research Institute Tasmania (Menzies) suggests that one of the main treatments for multiple sclerosis (MS) may also increase the amount of vitamin D patients receive ...

Hepatitis C drug can cause depression

May 01, 2012

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

Recommended for you

Time to take notice and tackle heart failure

12 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

15 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments